The Institute for Clinical and Economic Review (ICER) released a final report on new acute treatments for migraine attacks on 25 February that reversed some of the drug cost watchdog’s findings from its draft report released in January, giving Allergan PLC’s Ubrelvy (ubrogepant) and Biohaven Pharmaceutical Holding Co. Ltd.’s rimegepant a slight edge over Eli Lilly & Co.’s Reyvow (lasmiditan).
ICER’s draft report issued on 10 January determined that none of the three oral drugs used on-demand to stop migraine...




